Jump to a section
- Research scope and peptide identity
- Mechanisms discussed in cited studies
- Study models and experimental designs
- Outcomes measured in the reviewed sources
- Reported study-design and protocol details
- Reported study-design details from cited sources
- Limitations and research gaps
- Documentation checklist
- Related research supplies
- More Ipamorelin research
- Sources and references
Disclosure: Peptide Bio Index is affiliated with SourcePoint Research and may earn from qualifying purchases or affiliate links.
This article summarizes published research and reported study designs. It is not medical advice, dosing guidance, or a personal-use recommendation.
Source-limited research note: The reviewed sources were incomplete, ambiguous, or insufficient for a normal article. This page labels missing details rather than guessing.
This overview summarizes mechanistic claims and the experimental models used to study ipamorelin based only on the provided reviewed sources, emphasizing where protocols and outcomes were explicitly reported.
Research scope and peptide identity
Ipamorelin is described in the primary pharmacology report as a synthetic pentapeptide with the sequence Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH2 and was developed as a selective growth hormone (GH) secretagogue acting via a GHRP‑like receptor; this work characterized its in vitro GH releasing potency and in vivo GH release in animal models (rat pituitary cells, anaesthetised rats, and conscious swine) and noted a GH‑selective profile compared with other GHRPs (for example, lack of ACTH/cortisol release at doses >200‑fold the ED50 for GH) (S2). [S2]
Recent reviews place ipamorelin among growth hormone secretagogues and agents of interest for musculoskeletal, metabolic, and gerontological applications, while noting that much of the evidence remains preclinical and that clinical trial data are limited (S1, S3, S4, S5, S7). [S1] [S3] [S4] [S5] [S7]
Mechanisms discussed in cited studies
In the original pharmacology study, ipamorelin stimulated GH release via a GHRP‑like receptor in vitro and in vivo; its GH releasing potency and efficacy were quantified and compared with other GHRPs (S2). [S2]
Review articles cite GH secretagogues (including ipamorelin) as modulators of GH/IGF‑1 signaling relevant to tissue repair and body‑composition effects and place these actions in the broader context of regenerative signaling networks (for example, IGF‑1 activation and downstream pathways implicated in tissue regeneration) (S1, S6, S7). [S1] [S6] [S7]
A specific peripheral pharmacological effect reported in an animal study was inhibition of electrical field stimulation (EFS)‑induced contractions in isolated ferret ileum preparations by ipamorelin, indicating activity on enteric or smooth muscle responses in vitro (S8). [S8]
Study models and experimental designs
In vitro primary rat pituitary cell assays were used to determine ipamorelin's GH releasing potency and efficacy compared with GHRP‑6 (S2). [S2]
In vivo endocrine pharmacology was evaluated in pentobarbital‑anaesthetised rats and in conscious swine to quantify ED50 and maximal GH responses, allowing cross‑species comparison of potency and efficacy (S2). [S2]
A separate nonclinical study in ferrets used both isolated ileum preparations (ex vivo/in vitro pharmacology) and an in vivo cisplatin‑induced emesis model to test ghrelin‑mimetic compounds including ipamorelin; behavioral monitoring, food and water intake, and weight were recorded up to 72 hours after cisplatin administration (S8). [S8]
Preclinical murine models (murine glucocorticoid‑induced muscle loss) were cited in reviews as the context for combined CJC‑1295 + ipamorelin experiments that reported changes in maximum tetanic tension, though specific protocol details were not provided in the reviewed excerpt (S3). [S3]
Outcomes measured in the reviewed sources
Primary endocrine outcomes included GH release metrics: in vitro EC50 and Emax values from primary rat pituitary cells and in vivo ED50 and Emax measures in anaesthetised rats and conscious swine (S2). [S2]
Specificity outcomes reported in the original pharmacology work included measurements showing that ipamorelin did not significantly alter plasma FSH, LH, PRL, or TSH, and—unlike some other GHRPs—did not increase ACTH or cortisol at doses far exceeding the ED50 for GH release (S2). [S2]
In the ferret cisplatin model, outcomes included inhibition of EFS‑induced ileal contractions (quantified as percent inhibition and IC50 values for ileum preparations) and in vivo measures of food/water consumption and cisplatin‑associated weight change over an acute (up to 24 h) and delayed (48–72 h) period (S8). [S8]
A review‑summarized functional outcome in mice exposed to glucocorticoid‑induced muscle loss reported that CJC‑1295 combined with ipamorelin increased maximum tetanic tension in that murine model (S3). [S3]
Reported study-design and protocol details
The original preclinical pharmacology report provided quantitative potency and efficacy estimates: in vitro EC50 and Emax for GH release from primary rat pituitary cells and in vivo ED50 and Emax for pentobarbital‑anaesthetised rats and conscious swine; sequence identity and receptor pharmacology (GHRP‑like receptor) were also reported (S2). [S2]
In the ferret study, ipamorelin and anamorelin were tested intraperitoneally at 1–3 mg/kg administered 30 seconds before cisplatin (5 mg/kg, i.p.) and then every 24 hours, with behavior monitored for up to 72 hours; isolated ileum EFS experiments produced percent inhibition values and IC50 estimates for ileal contractility (S8). [S8]
Across the reviewed reviews, authors repeatedly note gaps in human clinical trial data, uncertainty about dosing regimens, frequency, and duration for clinical use, and the predominance of preclinical evidence—points emphasized without additional protocol specifics in the provided excerpts (S1, S3, S4, S5, S7). [S1] [S3] [S4] [S5] [S7]
Reported study-design details from cited sources
The following table summarizes protocol details reported in cited studies. These details are provided as literature context only and are not recommendations or instructions.
| Source | Study Type | Model / Subject | Amount Reported | Route Reported | Frequency | Duration | Notes |
|---|---|---|---|---|---|---|---|
| [S2] | Journal article, pharmacology | Primary rat pituitary cells; pentobarbital‑anaesthetised rats; conscious swine | In vitro EC50 (rat pituitary) = 1.3 +/- 0.4 nmol/l, Emax = 85 +/- 5%; anaesthetised rats ED50 = 80 +/- 42 nmol/kg, Emax = 1545 +/- 250 ng GH/ml; conscious swine ED50 = 2.3 +/- 0.03 nmol/kg, Emax = 65 +/- 0.2 ng GH/ml | not reported in the reviewed source | not reported in the reviewed source | not reported in the reviewed source | Peptide identity reported as pentapeptide Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH2; stimulated GH via a GHRP‑like receptor; did not significantly alter FSH, LH, PRL, or TSH and did not increase ACTH/cortisol at very high doses (S2). |
| [S8] | Research article, animal model | Ferret (in vivo cisplatin‑induced emesis/weight model) and isolated ferret ileum preparations (ex vivo/in vitro) | Anamorelin and ipamorelin 1–3 mg/kg (i.p. dose range tested); cisplatin 5 mg/kg (i.p.); ileum EFS IC50: anamorelin 14.0 µM (IC50), ipamorelin 11.7 µM (IC50); percent inhibition of EFS: anamorelin 94.4%, ipamorelin 54.4%; ipamorelin reduced cisplatin‑associated delayed‑phase weight loss by ~24% | Intraperitoneal (i.p.) for in vivo dosing; isolated ileum experiments performed ex vivo/in vitro | Administered 30 seconds before cisplatin and then every 24 hours | Behavior recorded for up to 72 hours; food and water consumption measured every 24 hours | Ipamorelin administered i.p. did not reduce acute or delayed emesis in this model but did attenuate delayed‑phase weight loss; central (intracerebroventricular) actions were reported for anamorelin but central ipamorelin effects were not reported in the reviewed excerpt (S8). |
Limitations and research gaps
- Most evidence in the provided sources is preclinical (in vitro, rodent, swine, ferret, and murine models); robust human clinical trial data for ipamorelin in orthopaedic or broader clinical indications were not reported in the provided excerpts.
- Several review authors explicitly note gaps in clinical safety, dosing, frequency, and duration information; specific human‑use protocols were not provided in the reviewed excerpts.
- Where mechanism or outcome claims are drawn from review articles, underlying primary data and methods are not fully detailed in the provided excerpts.
Documentation checklist
- Confirm whether additional, primary human clinical trials are available beyond the reviewed excerpts before making clinical inferences.
- Differentiate outcomes from in vitro, small animal, large animal, and review sources when interpreting translational relevance.
- Track explicit protocol details (dose, route, timing, frequency, duration) to avoid extrapolating from incomplete reports.
Related research supplies
- Freezer inventory labels and sample tracking sheets for peptide storage documentation
- Temperature‑monitored ultra‑low temperature freezer or cold storage log (documentation only)
- Laboratory notebook and electronic data capture templates for recording study design and outcomes
- Surface cleaning and decontamination supplies for laboratory benchtops and equipment (documentation of use and compatibility)
Research organization supplies: Common tools used for research documentation workflows may include lab notebooks, label makers, sample storage boxes, inventory stickers, and temperature log sheets.
Paid-link disclosure: Peptide Bio Index may earn a commission from qualifying purchases. As an Amazon Associate I earn from qualifying purchases.
Batch and inventory labeling
Phomemo M110 Label and Barcode Printer
A compact thermal label printer for inventory identifiers, storage-box labels, batch references, and document-folder organization.
Label-printer refill
Phomemo M110 White Replacement Labels
White 1.57 × 0.78 inch replacement labels for compatible Phomemo printers. Confirm printer and label-size compatibility before ordering.
Product listings, specifications, and availability can change. Review the current Amazon listing and manufacturer instructions before ordering. These links are for research organization and compatible surface/equipment-cleaning workflows, not personal-use guidance.
Research Supply Note: For research-use-only sourcing, review current SourcePoint Research inventory and batch documentation at SourcePointResearch.com. Peptide Bio Index is affiliated with SourcePoint Research.
Sources and references
- [S1] Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026. PMID: 41490200. DOI: 10.5435/JAAOSGlobal-D-25-00236
- [S2] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M. Ipamorelin, the first selective growth hormone secretagogue.. European journal of endocrinology. 1998. PMID: 9849822. DOI: 10.1530/eje.0.1390552
- [S3] Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.. The American journal of sports medicine. 2026. PMID: 41476424. DOI: 10.1177/03635465251357593
- [S4] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0
- [S5] Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.. International journal of molecular sciences. 2026. PMID: 42123471. DOI: 10.3390/ijms27093890
- [S6] Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.. Translational andrology and urology. 2020. PMID: 32257855. DOI: 10.21037/tau.2019.11.30
- [S7] Mavrych V, Shypilova I, Bolgova O. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.. Frontiers in aging. 2026. PMID: 42021992. DOI: 10.3389/fragi.2026.1790247
- [S8] Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.. Physiology & behavior. 2024. PMID: 39043357. DOI: 10.1016/j.physbeh.2024.114644
Peptide Bio Index is affiliated with SourcePoint Research. Articles may link to SourcePointResearch.com and third-party affiliate products. As an Amazon Associate, Peptide Bio Index earns from qualifying purchases. Content is educational and research-literature focused only and is not medical advice, dosing guidance, or a personal-use recommendation.